|
|
|
|
|
| Available: 0 |
| List Price:$19.99 |
|
|
| Edition: | 21th |
| Publisher: | Antimicrobial Therapy, Incorporated |
| ISBN: | 1-930808-73-9 (1930808739) |
| ISBN-13: | 978-1-930808-73-7 (9781930808737) |
| New Edition: | 1-930808-81-X |
| Format: | Hndbk/Pktbk/Tables |
| Binding: | Softcover |
| Copyright: | 2013 |
| Publish Date: | 12/12 |
| Volume: | 2013 |
| Weight: | 0.22 Lbs. |
| Pages: | 213 |
| Carton Quantity: | 100 |
| Subject Class: | INF (Infectious Disease) |
| Remarks: | A New Edition of this Title is Available |
| Return Policy: | Non-Returnable. |
| Table Of Contents: |
View
|
| Contributing Authors: |
View
|
|
|
| |
| ISSN Series: | Sanford Guide to HIV/AIDS Therapy | | Discipline: | Infectious Dis | | Subject Definition: | HIV Infections-Therapy-Handbooks | | NLM Class: | WC 39 | | LC Class: | RC607 | | Abstract: | The 2013 edition of The Sanford Guide to HIV/AIDS Therapy reflects the continuing evolution of HIV from epidemic to manageable chronic disease, at least in parts of the world with access to the latest antiretroviral drugs. New agents, such as rilpivirine, new combination ARV drug formulations, such as Stribild, and new guidelines on pre-exposure prophylaxis (PrEP) are included. ART recommendations have been updated in accordance with the most recent sets of guidelines and the section on HIV diagnostics have been revised to include newly available tests. We have undertaken a major revision of the sections on complication of ART and AIDS-related complications and opportunistic infections to reflect the changing understanding and management of HIV. In the previous edition, we expanded our focus to include a new section on Hepatitis C virus (HCV) infections. With this edition, we significantly expand our coverage of diagnosis and treatment of Hepatitis B virus infections. In many ways, the rapid development of novel treatments of HCV mimic remarkably the explosion of new drugs for HIV that emerged in the mid-1990s, constituting the HAART revolution. For the first time in over 20 years, outside of the release of pegylated interferon, two completely new drugs were released into practice to use in patients with HCV infection. These new NS3/4a protease inhibitors have improved the sustained virologic response (SVR), or cure, rate for HCV genotype 1 infections to levels unimaginable just 5 years ago. What's more, there are over 30 other new anti-HCV specific drugs in development that will further revolutionize the treatment of HCV over the next decade. |
|
|
|
|
|
|
Follow Matthews Book Co. on:
Copyright © 2001-2024 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews